Risk of Venous Thromboembolism (VTE)

*Further studies are ongoing or planned to collect sufficient data to estimate the risk. Therefore, the risks and benefits of use must be assumed to be as for other CHCs.¹

 

 

Conditions that increase the risk of VTE 3-6

 

 

  • The risk of VTE is highest in first year of CHC use3-6
  • The risk of VTE is increased when a CHC is re-started after a break in use of 4 weeks or more3-6

 

 

References:
1. Faculty of Sexual & Reproductive Healthcare Statement Venous Thromboembolism (VTE) and Hormonal Contraception November 2014 
2. European Medicines Agency Benefits of combined hormonal contraceptives (CHCs) continue to outweigh risks – 
CHMP endorses PRAC recommendation November 2013 EMA/709120/2013
3. Elvina® SPC
4. Elvinette® SPC
6. Violite® SPC

All available at www.medicines.ie